Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Manual for 6 famous sorts of cheddar - 26 Web-based Course Stages for Successful Learning and Educating
- 3Tech for Learning: Online Courses and Instructive Apparatuses
- 4Winter storms blanket the East, while the U.S. West is wondering: Where’s the snow?
- 5Sound Propensities: 20 Methods for helping Your Insusceptible Framework
- Jason Kelce opens about wife Kylie Kelce's past pregnancy loss
- AbbVie plans to build out its presence in obesity market
- How to watch the last supermoon of the year
- BHP liable for 2015 Brazil mine disaster: UK court
- The Best Web-based Courses for Ability Advancement
- Report in relation to renaming Herzog Park set to be withdrawn
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- Doomed SpaceX Starlink satellite photographed from orbit
- Arctic is again the hottest it's been in 125 years, with record-low sea ice, NOAA report says
